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Tissue factor pathway in haemostasis and beyond McVey 
 
Purpose of review: 
The role of tissue factor (TF) in the initiation of blood coagulation network leading to the generation 
of a fibrin clot has been well defined over the past 50 years. Although much is known about this 
sequence of events and its regulation many important questions remain unresolved. More recently, 
a complex role for TF in cellular processes independent of fibrin generation has emerged. This 
review summarizes some of the advances in this field. 
Recent findings: 
TF is the cellular receptor and cofactor for factor VII/VIIa however controversy still surrounds 
expression of TF within the vasculature, the role of circulating microvesicle pools of TF and 
mechanisms of ‘encryption’ of TF activity. However, there have been significant advances in the role 
of TF initiated cell signalling. Lastly, an alternatively spliced TF transcript has been identified and 
some insights into its role in cancer cell metastasis/proliferation have been elucidated. 
Summary: 
Understanding of TF structure-function has increased substantially however multiple controversies 
still surround some aspects of its regulation. TF has emerged as a pivotal player in orchestrating not 
only fibrin generation but in wound repair. Derangement of these repair processes contributes 
significantly to the pathophysiology of a number of disease processes. 
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Introduction 
The initiation of blood coagulation and subsequent wound repair is a fundamental defence 
mechanism conserved in all extant vertebrates [1,2]. The high blood pressure generated on the 
arterial side of the vertebrate circulation requires a powerful almost instantaneous but strictly 
localized procoagulant response in order to minimize blood loss from sites of vascular injury without 
compromising blood flow. In addition it interacts with other defence mechanisms, such as the 
immune system and the inflammatory response. At the heart of this complex network of interacting 
pathways is the cellular receptor tissue factor. 
 
Tissue Factor: structure and function 
Tissue factor (TF) also known as thromboplastin or factor (F) III is a 47kDa type 1 transmembrane 
glycoprotein that is the cellular receptor and cofactor for blood coagulation factor VII/VIIa 
(FVII/VIIa). The gene encoding human TF (F3) is located on chromosome 1 (1p22-p21) and spans 
12640 nucleotides and consists of 6 exons. The 2351 nucleotide mRNA transcript encodes a 295 
amino acid primary translation product that is processed to a mature TF protein of 263 amino acids 
in length after cleavage of the 32 amino acid signal peptide. The 219-residue extracellular region 
consists of two-fibronectin type III domains orientated at an angle of 125o (Figure 1) anchored into 
the cell membrane by a 23-residue transmembrane sequence followed by a 21 amino acid 
cytoplasmic tail. There are 3 N-linked glycosylation sites (N43, N156 & N169), 2 disulfide bridges 
(C81-C89 & C275-C295), an S-palmitoyl cycteine (C277) and a phosphorylated serine at position 290 
(all residues are numbered according to Goodeve et al (2011) [4] using HGVS nomenclature 
numbering the initiation methionine (+1) of the reference protein sequence (NP_001984) and may 
differ from previous publications by legacy numbering +32). These potential post-translational 
modification sites with the exception of the N-linked glycosylation site N156 are all highly conserved 
(Figure 1). 
 
Systematic site-directed mutagenesis [5-10] and x-ray crystallographic analysis [11-13] of TF and TF-
FVIIa complexes have identified the molecular determinants of FVII binding to TF. The extracellular 
region of TF binds tightly to FVII/FVIIa to form a highly active procoagulant complex. The 
extracellular region of TF is both necessary and sufficient for activity; as variants lacking either the 
21-residue cytoplasmic domain or both the cytoplasmic and transmembrane domains retain full 
procoagulant activities [14,15]. The substrates of the TF/FVIIa complex are FIX and FX. FVII, IX & X 
share a common protein structure, they are zymogens of vitamin K-dependent serine proteases with 
the domain architecture: γ-carboxylated (Gla) domain, epidermal growth factor (EGF) like domain 1, 
EGF like domain 2 and serine protease domain (Gla-EGF1-EGF2-SP; Figure 1). The Gla domain 
contains a number of glutamic acid residues that are post-translationally modified by addition of a γ-
carboxyl group in a vitamin K-dependent process. It forms a Ca2+ dependent fold that confers affinity 
to negatively charged phospholipid membranes. EGF-like domains are widely dispersed in nature 
and are often involved in protein-protein interactions. The serine protease domain is homologous to 
that of chymotrypsin. Although the structural elements responsible for the trypsin fold and 
archetypal catalytic triad serine, histidine and aspartate are highly conserved, amino acid 
substitutions to surface loops that border the active site and substrate recognition pocket confer 
diverse functional properties to the individual proteases [16]. FVII/VIIa interacts with the 
extracellular domain of TF primarily through the Gla and EGF-1 domains although the EGF2 and 
serine protease domains also contact TF [12]. Similarly, Gla and EGF-1 domains of the substrates, FIX 
and FX, represent the primary determinants in binding to TF-FVIIa and formation of the ternary 
complex [17,18]. A putative substrate-binding region (S195 G196 K197 K198) [7,19-21] that is highly 
conserved (Figure 1) in TF has been identified in binding FIX/FX through their Gla domains. The 
importance of Ca2+ ions in generating the characteristic loop structure of the Gla domain is well 
documented, however recently it has been shown that at physiologic concentrations of divalent 
cations Mg2+ occupies 2 or 3 of the divalent ion binding sites in the Gla domain. These results suggest 
that Mg2+ plays an important role in physiologic blood coagulation. Furthermore residues in the TF 
substrate-binding region have been implicated in binding the FX Gla domain in a Mg2+-dependent 
manner [13,22,23].  
 
Conversion of FVII to FVIIa is the result of a single proteolytic cleavage at Arg212–Ile213 
(nomenclature according to Goodeve et al [4], legacy numbering +60) peptide bond producing a 
disulfide-linked two-chain molecule. Unlike other members of the trypsin superfamily the neo N-
terminus generated upon activation of FVII fails to insert into the activation pocket leading to a non-
optimal alignment of the catalytic machinery, rendering FVIIa ‘zymogen like’ with significantly 
reduced catalytic activity. Binding of FVIIa to TF allosterically corrects this defect, transforming FVIIa 
into a catalytically competent enzyme. In addition, TF ensures optimal orientation and positioning of 
the FVIIa catalytic domain above the membrane surface for optimal interaction with its substrates 
(FIX & FX), thereby enhancing the proteolytic activity by 106-fold [24,25]. 
 
Tissue factor initiates blood coagulation 
Exposure of blood to cells expressing TF on their surface is both necessary and sufficient to initiate 
blood coagulation in vivo. FVII bound to TF is exquisitely sensitive to activation and while many 
enzymes are capable of converting FVII to FVIIa the most important one in vivo is likely FXa. 
However, how is this triggered if FXa is the product of TF-FVIIa? In blood 4% of total circulating FVII is 
in the form of FVIIa that has little functional activity in the absence of its cofactor TF [26]. It is this 
pool of FVIIa that most likely serves to prime the system to respond upon exposure to TF. Activation 
of FVII to the protease FVIIa and formation of a high affinity complex of TF-FVIIa results in activation 
of FIX and FX by the TF–FVIIa complex. A schematic of TF-initiated thrombin generation, including 
the important feedback reactions of thrombin, is shown in Figure 2.  
 
The TF–FVIIa complex is rapidly inactivated by tissue factor pathway inhibitor (TFPI) a Kunitz-type 
inhibitor released from thrombin-activated platelets or found on the surface of endothelial cells. 
TFPI inhibits TF-FVIIa by the formation of a quaternary inhibited complex of TF-FVIIa-FXa-TFPI in a 
FXa dependent manner (Figure 2) (Recently reviewed in [27,28]). The duration of the functional TF-
FVIIa complex is therefore dependent on the relative concentrations of TF and TFPI and these may 
vary at a particular site of vascular injury. This may help explain the differential bleeding phenotypes 
seen in different coagulation deficiencies. The sites most commonly affected by spontaneous 
bleeding in haemophilia A or B patients, skeletal muscle and joints, have undetectable to low TF 
expression. 
 
Mutations in the gene encoding TF would be predicted to lead to either a bleeding (loss of function) 
or a prothrombotic (gain of function) phenotype; however no congenital abnormalities have been 
described to date. Targeted disruption of the mouse TF gene (f3) results in embryonic lethality of f3-/- 
embryos at embryonic days 9.5-10.5 [29-31] and therefore loss in early pregnancy most probably 
accounts for the lack of TF deficient individuals seen in clinical practice. 
 
Tissue factor expression 
TF is constitutively expressed on extravascular cells of many tissues such as skin, organ surfaces, 
vascular adventitia and epithelial–mesenchymal surfaces [32,33]. The cellular distribution of TF at 
biological boundary layers led to the proposal that it functions as a ‘haemostatic envelope’, ensuring 
that following disruption of vascular integrity blood is immediately exposed to cells expressing TF, 
leading to the initiation of blood coagulation. 
 
Cells within the vasculature including endothelial cells (EC) do not normally express TF. However, 
induced expression of TF in cells within the vasculature is implicated in the pathogenesis of 
thrombosis in atherosclerosis [34], disseminated intravascular coagulation [35], malignancy [36] and 
hyperacute rejection of zenografts [37]. In vitro TF expression can be induced in ECs and monocytes 
by a variety of agonists. TF expression is primarily controlled at the transcriptional level although 
post-transcriptional stabilization of TF mRNA also contributes to its rapid induction [38,39]. The 
proximal promoter has been extensively studied and cis- and trans-acting factors required for 
appropriate gene regulation in vitro have been characterised (reviewed in [40]). Induction of TF 
mRNA following stimulation occurs rapidly and peaks at 2h. TF protein levels on the cell surface peak 
at 4h and these remain high for up to 24h. Although the response of both monocytes and ECs in vitro 
to a variety of different agonists has been well documented and shown to be very similar, evidence 
for EC expression of TF in vivo is scant and remains controversial. In an experimental model of Gram 
negative sepsis in baboons EC expression of TF was reported only in the splenic vasculature [41]. 
More recent data using this model demonstrated immune-reactive TF in the aorta, however this was 
restricted to granular structures on the surface of ECs and it could not be determined whether the 
TF was produced by ECs or transferred to the EC surface [42]. Two studies in mice and rabbits have 
reported TF immunoreactivity in ECs following treatment with lipopolysaccharide (LPS) but the data 
is open to other interpretation [43,44]. In contrast, a number of other studies have failed to detect 
TF expression in ECs in LPS treated mice and rabbits [40,45-47]. Genetic approaches to generate cell 
lineage-specific TF gene deletion transgenic mice has shown that TF expression in ECs in vivo does 
not contribute to the initiation of coagulation in a mouse model of endotoxemia or carotid artery 
thrombosis. In contrast, in vivo induced expression of TF on monocytes/macrophages is clearly 
associated with disease conditions. Rupture of atherosclerotic plaques exposes a large amount of TF 
expressed on macrophage derived foam cells leading to thrombosis and myocardial infarction. In 
endotoxemic animals and humans monocytes express TF leading to disseminated intravascular 
coagulation.  
 
Another controversial and complex area of interest is that of ‘blood borne’ extracellular TF and its 
role in propagation of thrombosis. Immuno-reactive TF is detectable in plasma either as a soluble 
protein or on circulating microparticles (MPs; also known as microvesicles or extracellular vesicles). 
MPs are defined as heterogeneous, submicron (0.1-1 µm) vesicles released from cells in response to 
various stimuli. They have an intact phospholipid bilayer membrane and carry membrane proteins 
specific to their cellular origin. However, transfer from one MP to another or to other cell types via 
specific receptor-mediated interactions or fusion may mean surface antigens do not accurately 
reflect their cellular origins. Under normal conditions cells maintain a phospholipid asymmetry with 
negatively charged PS confined primarily to the inner leaflet of the plasma membrane. The collapse 
of this asymmetry appears critical to the formation of MPs and therefore the majority are PS 
positive, as assessed by binding of fluorescently labelled annexin V or lactahedrin. The role of MPs in 
many pathological conditions, including thrombosis, has been extensively studied (Recently 
reviewed in [48]). The contribution of MPs to a procoagulant phenotype may arise through the 
provision of a negatively charged phospholipid surface to promote the assembly of the procoagulant 
complexes or because the MPs are also TF positive. MPs positive for TF are low to undetectable in 
healthy individuals but increase significantly in various pathological conditions. The analysis of 
circulating MPs and their procoagulant phenotype is however fraught with difficulties as pre-
analytical parameters can impact the outcome. These include: the type of anticoagulant, 
phlebotomy, transport, centrifugation and freezing of blood samples. The International Society of 
Thrombosis and Haemostasis (ISTH) issued guidance on standardization of protocols to reduce 
variability in sample preparation [49]. Similarly, there are several analytical variables that can affect 
the detection and quantification of MPs by flow cytometery, which is the most common method of 
MP analysis in biological samples. These include: the type of flow cytometer and its ability to 
measure submicron particles, gating strategies and the choice of assay to detect TF. The ISTH has 
also established a standardized method for quantification of MPs by flow cytometery that uses size 
calibrated fluorescent beads which may help to address some of these issues [50]. MP TF levels can 
be measured either antigenically using flow cytometry or ELISA or functionally by measuring FXa 
generation. In the case of antigen measurement careful choice of appropriate antibodies is essential 
to ensure specific detection of total TF. For example, the inhibitory anti-human TF monoclonal 
antibody HTF-1 completes with FVII/FVIIa for binding to TF and may not adequately detect TF-FVII 
complex thereby underestimating TF levels [51]. Plasma TF concentrations have been quantified in 
multiple studies using the Imubind TF ELISA (American Diagnostica) which uses monoclonal capture 
and polyclonal detection antibodies, however comparison of results obtained with other monoclonal 
assays suggest the Imubind assay detects other cross-reactive proteins and may not accurately 
reflect plasma TF levels [52]. Activity assays offer the advantage of specificity and sensitivity as well 
as detecting functional TF-FVIIa activity toward its macromolecular weight substrate FX [53]. 
However, it should be noted that antigen and activity based assays may not correlate with each 
other, which may be a result of TF encryption (discussed below) rather than a technical problem 
with the assays.  
 
Tissue factor encryption 
In virtually every cell type TF exists in two forms: a latent or encrypted form that binds FVII/FVIIa but 
does not activate FX and an active or de-encrypted form that activates FX to FXa and is therefore 
procoagulant. Both forms of TF are expressed on the surface of cells and encrypted TF can be 
converted to a procoagulant active form in a number of experimental ways that include cell lysis, 
calcium ionophore treatment or LPS, thrombin or cytokoine treatment. The mechanism(s) that 
regulate the activity of TF are controversial. The two schools of thought will be briefly described in 
this review but the reader is referred to the following articles for an in depth discussion of the 
conflicting views [54,55].  
 
Membrane phospholipid asymmetry is actively maintained by the action of a number of molecular 
mechanisms involving: flippases (transport PS to the inner leaflet), floppases (transport PS to the 
outer leaflet) and scrablases (transport PS bidirectionally). Inhibition or activation of any of these 
enzymes may lead to a collapse of the PS asymmetry. The phospholipid content of membranes has a 
significant impact on the procoagulant function of TF. Relipidation of purified TF in vesicles 
containing PS greatly accelerates TF procoagulant activity. One school of thought is that TF 
procoagulant activity is regulated by the local phospholipid microenvironment. An alternative school 
of thought suggests TF is encrypted in an inactive form by reduction of the disufide bond closest to 
the membrane (C275-C295) and activated by oxidation to form the disulfide bond. It is proposed 
that this thiol-disulfide exchange is regulated by protein disulphide isomerase (PDI), an abundant 
oxido-reductase predominantly expressed in the lumen of the endoplasmic reticulum but secreted 
and associated with the surface of various cell types, including platelets, monocytes and 
macrophages. The role of the disulfide bond in TF function remains controversial and has polarised 
opinion.  
 
Tissue factor signalling 
As discussed above the TF-FVIIa complex catalyses the activation of FIX and FX leading to thrombin 
generation and subsequently formation of a fibrin clot. Over the last twenty years it has become 
clear that activated coagulation proteases play an important role in cellular signalling independent of 
fibrin generation. This occurs through activation of protease-activated receptors (PARs), a subfamily 
of seven-transmembrane G-protein-coupled receptors. There are four members of the PAR family 
(PAR-1, -2, -3 and -4) encoded by the their respective genes (F2R, F2LR1, F2RL2 and F2RL3). Their 
unique mechanism of activation involves specific enzymatic cleavage of the PAR extracellular 
domain, generating a neo-amino terminus that functions as a ‘tethered ligand’ by binding intra-
molecularly and generating an intracellular signal through G-proteins leading to PI hydrolysis, Ca2+ 
transients and activation of intracellular kinases. Vitamin K-dependent coagulation factors with the 
exception of FIXa are able to selectively activate cell surface PARs. Thrombin can directly activate 
PAR-1, -3 and -4 but not PAR-2, however PAR-2 can be trans-activated by thrombin activated PAR-1 
when the N-terminal PAR-1 tethered ligand is able to interact with the binding pocket of an adjacent 
PAR-2 receptor. Although thrombin can activate both PAR-1 and PAR-4 markedly higher 
concentrations of thrombin are required to activate PAR-4. FXa can directly activate both PAR-1 and 
-2 as well as through the ternary TF-FVIIa-FXa complex, whereas the TF-FVIIa complex can only 
activate PAR-2. The PARs activation has been shown to elicit intracellular signalling that results in a 
plethora of cellular responses including proliferation, migration, cell shape change, secretion of 
cytokines/chemoattractants, degranulation as well as the initiation of various transcriptional 
responses. It has become clear that coagulation protease activation of PARs plays an important role 
in normal haemostasis, vascular development, inflammation in a variety of disease models, cancer 
biology as well as fibrosis seen in a number of pathological situations across all major organ systems 
[56]. 
 
Coagulation protease signalling through PARs is complex. PARs are expressed on a variety of 
different cell types in a cell-type specific manner; however the same cell type isolated from different 
sources may display different expression patterns of PARs. For example, primary fibroblasts of 
different origin (dermal vs lung) show distinct PAR expression profiles and respond differently to FXa 
stimulation in vitro [57]. Similarly, ECs from different origins have been shown to respond differently 
to PAR agonist peptides suggesting differential PAR expression [58]. Furthermore, although following 
tissue injury cells may be exposed to blood containing FVII/FVIIa, FX and prothrombin, in the 
absence of tissue damage the source of coagulation factors may be local and may not reflect the 
makeup or concentrations found in plasma and therefore protease specific responses may occur [59-
62]. Initially, because TF-FVIIa and FXa ultimately lead to the generation of thrombin and PAR-1 
signalling the significance of the other protease complexes in activating PARs and initiating cellular 
responses was largely overlooked. However, the recognition that PAR-2 signalling plays a key role in 
a number of pathological responses has reignited interest in FXa as an important mediator of 
inflammatory responses [63]. 
 
Alternatively Spliced Tissue factor  
This review has concentrated on the expression and function of full-length TF, however another 
isoform of TF generated by alternative splicing of the TF transcript has been described [64]. The 
alternatively spliced TF mRNA transcript lacks exon 5 which results in a translation product (AS-TF) of 
206 amino acids that shares the first 166 amino acids with full-length TF but lacks 3 of the β–strands 
(E, F & G) that comprise the C-terminal immunoglobulin-like domain which includes the disulfide 
bridge C275-C295 (Figure 3). In addition AS-TF also lacks the transmembrane and cytoplasmic 
domains and is therefore a soluble protein with a unique 40 amino acid C-terminus (Figure 3). The 
unique neo-C-terminus does not appear to be highly conserved as protein database searches fail to 
identify TF sequences with sequence identity with the exception of some primate sequences. The 
mouse AS-TF mRNA has been cloned [65] and the sequence of the C-terminal region shares limited 
amino acid identity (18/40) and is an additional 53 amino acids longer. The expression pattern of AS-
TF essentially mirrors that of full-length TF but it is expressed at significantly lower levels. Perhaps 
not surprisingly given its structure AS-TF has no procoagulant activity. However, AS-TF has been 
associated with increased cancer cell migration, invasion, metastasis and proliferation. The effect of 
AS-TF appears to be mediated through direct interaction with integrins (αvβ3 and α6β1), leading to 
activation of cell signalling and subsequent modulation of cancer cell biology [66-68]. In contrast to 
full-length TF the biological actions of AS-TF appear to be independent of PAR signalling.  
 
Conclusion 
Tissue factor is a cellular receptor that plays a pivotal role in regulating the initiation of blood 
coagulation and wound repair processes. Despite many decades of research that have increased our 
understanding of the structure and function of this molecule there still remains much to learn about 
its role in the pathophysiology of disease.  
 
Key points 
• TF is the cellular receptor and cofactor for blood coagulation factor VII/VIIa 
• Exposure of flowing blood to cells expressing TF is sufficient and necessary to initiate blood 
coagulation 
• TF initiated thrombin generation leads to cellular signalling through activation of PARs 
• TF initiated cellular signalling plays a pivotal role in pathophysiology of a number of diseases 
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Figure Legends: 
Figure 1:  
A: Multiple sequence alignment of predicted amino acid sequences encoding TF from various 
species. The accession number (gi) of each sequence is given. Sequences were aligned using Clustal 
W [3]. The transmembrane domain sequence is boxed. Disulfide bonds are indicated by square 
brackets. N-linked consensus glycosylation sites are indicated by ∗. The putative substrate-binding 
region is indicated by . The percent identity and similarity of each sequence with the human 
reference sequence is given. 
B: Molecular model of the complex between active site inhibited factor VIIa and the extracellular 
domain of tissue factor (PDB: 1DAN). FVIIa protein chain is represented by a grey ribbon. The active 
site inhibitor is shown in ball and stick. Calcium ions are represented by red spheres. The TF protein 
chain is represented by a green ribbon with residues conserved in all species analysed shown in blue. 
 
Figure 2: 
Schematic representation of the blood coagulation network initiated by exposure of flowing blood to 
cells expressing TF.  
Formation of a high affinity complex of TF-FVIIa results in activation of FIX and FX by the TF–FVIIa 
complex. In the absence of its activated cofactor FVa, FXa generates only trace amounts of thrombin 
from prothrombin. Although insufficient to initiate significant fibrin polymerization, thrombin 
formed in this initiation stage of coagulation is able to back-activate FV, FVIII and FXI by limited 
proteolysis and to activate platelets providing a negatively charged surface for the assembly of 
procoagulant complexes. In the amplification phase of coagulation, FXIa activates further FIXa which 
forms a complex with FVIIIa. This is the intrinsic tenase complex (FVIIIa–FIXa) that activates sufficient 
FXa to form a complex with FVa, producing the prothrombinase complex (FVa–FXa). This results in 
the explosive generation of thrombin that ultimately leads to generation of a fibrin clot. A key 
feature of these processes is the assembly of multimolecular complexes on phospholipid surfaces 
provided by activated platelets. Each of these complexes consists of a cofactor (TF, FVa, FVIIIa), an 
enzyme (FVIIa, FIXa, FXa) and a substrate that is a zymogen (FIX, FX and prothrombin) of a serine 
protease. The product of one reaction becomes the enzyme in the next complex. The cofactors FV 
and FVIII are themselves activated by limited proteolytic digestion. Positive feedback loops are 
represented by red dashed lines, negative feedback loops by blue dashed lines. 
 
Figure 3: 
A: Sequence alignment of predicted amino acid sequences encoding full-length TF (FL-TF) and 
alternatively spliced TF (AS-TF). The amino acid sequence in common is shaded black. The 
transmembrane domain sequence is shaded grey. Disulfide bonds are indicated by square brackets. 
Molecular model the extracellular domain of tissue factor (PDB: 1DAN). The TF protein chain is 
represented by a green ribbon with residues conserved in all species analysed shown in blue. B: 
represents FL-TF and C: represents AS-TF demonstrating the loss of 3 of the β–strands that comprise 
the C-terminal immunoglobulin like domain.  
                       10        20        30        40        50         60           
              ....|....|....|....|....|....|....|....|....|....|....|....| 
Human  SGTTNTVAAYNLTWKSTNFKTILEWEPKPVN-QVYTVQISTKSGD--WKSKCFYTTDTEC  
Cow  AGTTDVVVAYNITWKSTNFKTILEWEPKPIN-HVYTVQISPRLGN--WKNKCFYTTNTEC  
Dog  SGTADVVVAYNLTWKSTNFKTILEWEPKPIN-HVYTVQISPRLGN--WKSKCFYTTDTEC  
Mouse  AGIP--EKAFNLTWISTDFKTILEWQPKPTN-YTYTVQISDRSRN--WKNKCFSTTDTEC  
Rat  AGTPP-GKAFNLTWISTDFKTILEWQPKPTN-YTYTVQISDRSRN--WKYKCTGTTDTEC  
Chicken  AGNPELPTAVNITWSSINFKTILKWQPKPSG-YFYTVEIHGQMSD--TKKKCVMTTETEC  
Frog  TETTSIGKAVNVRWSSINGKTIIEWEPKPIN-YTYTVEVAGEGAN--WKRKCIHTTATEC  
Zebra fish  MDVGKLTKATNVSWTSYNFKTILSWGPKPVN-YTYTVEFSRTNRDKQRNPHCIRSTETEC  
Puffer fish  ---ASYPRAYNVTWKSTNFKTVLTWDPKPSHLYSYTVEFFRIGGDKMRNPHCIRSSFPQC  
 
                       70        80        90       100       110       120         
              ....|....|....|....|....|....|....|....|....|....|....|....| 
gi|4503641  DLTDEIVKDVKQTYLARVFSYPAGNVESTGSAG--------EPLYENSPEFTPYLETNLG  
gi|27806949  DVTDEIVKNVRETYLARVLSYPA---DTSSSTV--------EPPFTNSPEFTPYLETNLG  
gi|66864907  DLTDEIVNDVHQTYQARVFSYPA---DATDYSG--------EPPFTNSPEFIPYIETKLG  
gi|170172540  DLTDEIVKDVTWAYEAKVLSVPRR--NSVHGDGDQLVIHGEEPPFTNAPKFLPYRDTNLG  
gi|52138595 DLTDEIVKDVNWTYEARVLSVPWR--NSTHGKETLFGTHGEEPPFTNARKFLPYRDTKIG  
gi|513197076  DVTDALRN-VKETYTAHVLSVKS---LVEDNFE--------EPLFASSEKFTPYNQTIIG  
gi|148225476  DVTDLLEN-VNDTYTARIISEVQ---DTEDFTE--------EFPYTDSPPFVPYKQTIIG  
gi|611434991  DLT-NDL-DINEVYSAEVLSEPL---PSMNIDQV-------EPPYSRSKIFRPYDDTLIG  
gi|768954012  DLS-NSLTELRSSYMAEILSEPP---LGETSELT-------EFPYSRSPRFCPYNDTDIG  
 
                      130       140       150       160       170       180      
              ....|....|....|....|....|....|....|....|....|....|....|.**** 
gi|4503641  QPTIQSFE--QVGTKVNVTVEDERTLVRR-NNTFLSLRDVFGKDLIYTLYYWKSSSSGKK  
gi|27806949  QPTIQSFE--QVGTKLNVTVQDARTLVRA-NSAFLSLRDVFGKDLNYTLYYWKASSTGKK  
gi|66864907  QPTIQSFK--QVGTELNVIVQDARTLVKV-NGTFLSLRDVFGKDLSYTLYYWKASSTGKK  
gi|170172540  QPVIQQFE--QDGRKLNVVVKDSLTLVRK-NGTFLTLRQVFGKDLGYIITYRKGSSTGKK  
gi|52138595  QPVIQKYE--QDGTKLKVTVKDSFTLVRK-NGTFLTLRQVFGNDLGYILTYRKDSSTGRK  
gi|513197076  KPEIQHH--TQKDSKLTVVFRDPLTPYMFPNGSFQSVRDIFKHDLEYKLYYWKDQSSGKK  
gi|148225476  KPVIESYNFSKDITKLTVIVKDPLTPYRFSNGSFKSVRDIFNNDFEYTVFYRRASSTGKK  
gi|611434991  RPQFTLTVS-IDKK-LVLTIQDPITALHK-DNRSLNIRDIFKKNLKYKVAYSKAGSTGKK  
gi|768954012  KPDFKLEVS-ADKKKTSLFVTDPLTALFK-DGRQLNIRDIFSDQLMYKVTYRKNKSTGKK  
 
                      190      200       210       220       230       240      
              ....|....|....|....|....|....|....|....|....|....|....|....| 
gi|4503641  TAKTNTNEFLID-VDKGENYCFSVQAVIPSRT-VNRKSTDSPVECMGQEKGEFR----EI  
gi|27806949 KATTNTNGFLID-VDKGENYCFHVQAVILSRR-VNQKSPESPIKCTSHEKVLST----EL  
gi|66864907  TAKTNTNEFLID-VDEGQNYCFSVQAGIPSRK-ANQKSPESPIECTSHEKGMFR----EM  
gi|170172540  TNITNTNEFSID-VEEGVSYCFFVQAMIFSRK-TNQNSPGSSTVCTEQWKSFLG----ET  
gi|52138595  TNTTHTNEFLID-VEKGVSYCFFVQAVIFSRK-TNHKSPESITKCTEQWKSVLG----ET  
gi|513197076  DATTKSHTFDIS-VDNKNNYCFYVQGIIPSRR-ENRNGQESTVLCTTVGRTILDEYGAEV  
gi|148225476  QETSNSNEIVVN-VDQGESYCFYVQATIPSRS-QNRDSQVSEEKCTTASKN---------  
gi|611434991  IKVVEESRAEFNRLDEDQSYCFSVAAYIPNRKGDKRLGEWSLPKCSPQESKSLF--EEYG  
gi|768954012  EHISKTNVIELTNLDQGESYCFSIQAYIPSRTITKQLGEESQFQCS----------EENS  
 
                      250       260       270       280    
              ....|....|....|....|....|....|....|....|...   % Identity  % Similarity 
gi|4503641  FYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS  
gi|27806949  FFIIGTVMLVIIIFIVVLSVSLHKCRKVRAERSGKENTPLNAA        70      84 
gi|66864907  FLVIGIVVLVVIIFTIILSVSLYKCRKVRARQSGKESTPLNAA        73         84
gi|170172540  LIIVGAVVLLATIFIILLSISLCKRRKNRAGQKGK-NTPSRLA        54         66 
gi|52138595  LIIVGAVVFLVTVFIILLTISLCKRRKNRAGQKRK-NTPSRLA        55         67 
gi|513197076  FIIIAVVAIAVITLTIILAVILCKCKRAKN---AREKEPLNGV        43         56 
gi|148225476  ----AASAVGSTSEFIFLCSWMLLCCLL---------------        37         53        
gi|611434991  LAVIGGAALATLAFVIAVIVLIVVCCKRAQKQTPTAKETIV--        31         46 
gi|768954012  SILKGKAESESESDLFIAIVHVVHSITQAR-------------        28         46 
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              10         20         30         40         50         60             
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
FL-TF  SGTTNTVAAY NLTWKSTNFK TILEWEPKPV NQVYTVQIST KSGDWKSKCF YTTDTECDLT   
AS-TF  SGTTNTVAAY NLTWKSTNFK TILEWEPKPV NQVYTVQIST KSGDWKSKCF YTTDTECDLT   
               70         80         90        100        110        120            
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
FL-TF  DEIVKDVKQT YLARVFSYPA GNVESTGSAG EPLYENSPEF TPYLETNLGQ PTIQSFEQVG   
AS-TF  DEIVKDVKQT YLARVFSYPA GNVESTGSAG EPLYENSPEF TPYLETNLGQ PTIQSFEQVG   
              130        140        150        160        170        180           
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
FL-TF  TKVNVTVEDE RTLVRRNNTF LSLRDVFGKD LIYTLYYWKS SSSGKKTAKT NTNEFLIDVD   
AS-TF  TKVNVTVEDE RTLVRRNNTF LSLRDVFGKD LIYTLYYWKS SSSGKKYSTS LELWYLWSSS   
              190        200         210       220        230        240           
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
FL-TF  KGENYCFSVQ AVIPSRTVNR KSTDSPVECM GQEKGEFREI FYIIGAVVFV VIILVIILAI   
AS-TF  LSSSWLYLYT SVERQEWGRA GRRTPH                                        
              250        260     
      ....|....| ....|....| ...  
FL-TF  SLHKCRKAGV GQSWKENSPL NVS  
AS-TF 
B.       C. 
                            
  
